Confirmed cases of mpox in Santa Catarina: case profile and disease incidence, 2022–2024
DOI:
https://doi.org/10.17058/reci.v16i.20589Keywords:
Mpox, Descriptive Epidemiology, Monkeypox virus, Epidemiological Profile, Public Health SurveillanceAbstract
Background and Objectives: Updated analyses of mpox data are essential to understand transmission patterns and the epidemiological profile of cases, providing evidence to support targeted and effective public health actions. This study aimed to describe the epidemiological profile of confirmed mpox cases and to analyze the incidence of the disease in the state of Santa Catarina, Brazil, from 2022 to 2024. Methods: A descriptive study was conducted using confirmed mpox cases reported in Santa Catarina between 2022 and 2024, obtained from Tabnet/DIVE. Absolute (n) and relative (%) frequencies of cases were described, and incidence rates and the evolution of the moving average were analyzed. The variables were analyzed using Stata software, version 14. Results: A total of 510 confirmed mpox cases were recorded during the study period, with most cases occurring in 2022 (85.5%). A moving average of 115 cases was observed during the period. A higher proportion of cases was observed among males (94.5%) and younger age groups, particularly those aged 20–39 years (79.2%). Higher incidence rates were also observed in Grande Florianópolis in 2022 (17.9 per 100,000 population). Most cases occurred among individuals who identified as homosexual (68.4%) and cisgender men (73.5%). The main reported route of transmission was physical contact (47.6%). Conclusion: Most cases occurred in 2022, with predominance among males, young adults, homosexual individuals, and cisgender men. This profile highlights the need to strengthen prevention and health communication actions targeted at the most affected groups, contributing to disease control.
Downloads
References
1. Karagoz A, Tombuloglu H, Alsaeed M, et al. Monkeypox (mpox) virus: classification, origin, transmission, genome organization, antiviral drugs, and molecular diagnosis. J Infect Public Health. 2023;16(4):531-541. https://doi.org/10.1016/j.jiph.2023.02.003
2. Farahat RA, Sah R, El-Sakka AA, Benmelouka AY, Kundu M, Labieb F, et al. Human monkeypox disease (MPX). Le Infezioni Med. 2022;30(3):372–91. . https://doi.org/10.53854/liim-3003-6
3. Santa Catarina. Secretaria de Estado da Saúde. Informe Monkeypox nº 34/2024 [2022]. Available from: https://dive.sc.gov.br/phocadownload/doencas-agravos/Monkeypox/Informes/Informe-MPX34-2024.pdf
4. Agência Nacional de Vigilância Sanitária (ANVISA). Mpox: o que é, sintomas, prevenção e mais. Brasília: ANVISA. Available from: https://www.gov.br/anvisa/pt-br/assuntos/campanhas/monkeypox
5. Nuzzo JB, Borio LL, Gostin LO. The WHO Declaration of Monkeypox as a Global Public Health Emergency. JAMA. 2022 Aug 16;328(7):615. https://doi.org/10.1001/jama.2022.12513
6. Gostin LO, Hodge JG Jr, Wiley LF. Mpox and the Global Health Emergency: What Are the Lessons? N Engl J Med. 2024 Apr 25;390(17):1603–5. https://www.nejm.org/doi/full/10.1056/NEJMp2410395
7. Brasil. Ministério da Saúde. Brasil confirma primeiro caso de monkeypox. Brasília: Ministério da Saúde; 2022. Available from: https://www.gov.br/saude/pt-br/canais-de-atendimento/sala-de-imprensa/notas-a-imprensa/2022/brasil-confirma-primeiro-caso-de-monkeypox
8. Ribeiro CLP, D’Oliveira CAFB, Campos ÉA, Carvalho LF, Pinto LA, Duffrayer KM, et al. Notified cases of mpox in the city of Rio de Janeiro, Brazil: a descriptive study, 2022. Epidemiol Serv Saúde. 2024;33:e2023899. https://doi.org/10.1590/S2237-96222024v33e2023899.en
9. Pascom ARP, Souza IN de, Krummenauer A, Duarte MMS, Sallas J, Rohlfs DB, et al. Características epidemiológicas e clínicas dos casos de monkeypox no Brasil em 2022: estudo transversal. Epidemiol Serv Saúde. 2022;31(3):e2022851. https://doi.org/10.1590/S2237-96222022000300036
10. Diretoria de Vigilância Epidemiológica de Santa Catarina (DIVE/SC). TABNET – DIVE/SC. Florianópolis (SC): Secretaria de Estado da Saúde de Santa Catarina. Available from: http://tabnet.dive.sc.gov.br/
11. Brasil. Ministério da Saúde. Departamento de Informática do SUS (DATASUS). TABNET – Projeção da população 2024: Unidades da Federação [Internet]. Brasília (DF): DATASUS. Available from: http://tabnet.datasus.gov.br/cgi/deftohtm.exe?ibge/cnv/projpop2024uf.def
12. Santa Catarina. Secretaria de Estado da Saúde. Diretoria de Vigilância Epidemiológica. Manual de orientações da Monkeypox (MPX). Florianópolis: DIVE/SC; 2022. Available from: https://dive.sc.gov.br/phocadownload/doencas-agravos/Monkeypox/Publicacoes/manual-monkeypox17-10-2022.pdf
13. Pereira PLG, Flores ERM, Silva TPR, Faria APV, Ribeiro EEN, Sato APS, et al. Epidemiology of monkeypox notifications in the state of Minas Gerais, Brazil. Rev Bras Enferm. 2023;76(3):e20220598. https://doi.org/10.1590/0034-7167-2022-0598pt
14. Sousa AFL, Sousa AR, Fronteira I. Monkeypox: between precision public health and stigma risk. Rev Bras Enferm. 2022;75(5):e750501. https://doi.org/10.1590/0034-7167.2022750501
15. Pinheiro DAR, Bahia AGMFM. As recomendações em saúde pública como microagressões: varíola dos macacos e populações LGBTQIA+. Cad Saúde Pública. 2023;39(10):e00020623. Available from: https://doi.org/10.1590/0102-311XPT020623
16. Gao S, Zeng Z, Zhai Y, et al. Driving effect of multiplex factors on Mpox in global high-risk region, implication for Mpox based on one health concept. One. Jul 2023:100597. Disponível em: https://doi.org/10.1016/j.onehlt.2023.100597
17. Ugwu CL, Asgary A, Wu J, et al. Geographical distribution and the impact of socio-environmental indicators on incidence of Mpox in Ontario, Canada. PloS one. 2025 Mar 11;20(3):e0306681. https://doi.org/10.1371/journal.pone.0306681
18. Đurić P, Jovanović V, Drakulović MB, et al. Mpox cases in Serbia, 2022. Infect Dis Rep. 2025;17(1):9. https://doi.org/10.3390/idr17010009
19. Santa Catarina. Secretaria de Estado da Saúde. Diretoria de Vigilância Epidemiológica. Plano de Contingência Estadual para Monkeypox (MPX). Florianópolis: DIVE/SC; 2022. Available from: https://dive.sc.gov.br/phocadownload/doencas-agravos/Monkeypox/Publicacoes/PC-Monkeypox-25-08-2022.pdf
20. Brasil. Ministério da Saúde. Departamento do Programa Nacional de Imunizações; Coordenação-Geral de Incorporação Científica e Imunização. Informe Técnico Operacional de Vacinação Contra a Mpox. Brasília: Ministério da Saúde; 2023 Aug 13. Disponível em: https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/m/mpox/publicacoes/informe-tecnico-operacional-de-vacinacao-contra-a-mpox
21. Silva RM, Kobayashi CD, Martins AF, et al. Estudo descritivo dos eventos supostamente atribuíveis à vacinação contra a mpox no Brasil em 2023. Cad Saude Publica. 2024;40(10). Disponível em: https://doi.org/10.1590/0102-311xpt006624
22. Zhang X, Liu DA, Qiu Y, et al. Recent advances in Mpox epidemic: global features and vaccine prevention research. Vaccines. 2025;13(5):466. https://doi.org/10.3390/vaccines13050466
23. Irfan Khan M, Saleh AA, Ali R, Jan RU, Gu J, Dejun J. The evolving mpox threat (2022-2024): clade dynamics, immune evasion, and escalating global health challenges. Front Cell Infect Microbiol. 2026 Feb 9;15:1677762. https://doi.org/10.3389/fcimb.2025.1677762
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Regina Célia Santos Valim, Danúbia Hillesheim, André Silva Wagner, Ana Luiza Curi Hallal
This work is licensed under a Creative Commons Attribution 4.0 International License.
The author must state that the paper is original (has not been published previously), not infringing any copyright or other ownership right involving third parties. Once the paper is submitted, the Journal reserves the right to make normative changes, such as spelling and grammar, in order to maintain the language standard, but respecting the author’s style. The published papers become ownership of RECI, considering that all the opinions expressed by the authors are their responsibility. Because we are an open access journal, we allow free use of articles in educational and scientific applications provided the source is cited under the Creative Commons CC-BY license.
